Accordingly, an ongoing Phase II clinical study (NCT03179904) will further investigate the efficacy and safety profile of TVB-2640 administered in conjunction with trastuzumab plus paclitaxel or endocrine therapy in the management of advanced HER2-positive breast cancer (Table 1). Here, ERBB2 is linked to breast carcinoma.